Lymphomas encompass a diverse group of malignant lymphoid neoplasms. Over recent years much scientific effort has been undertaken to identify and understand molecular changes in lymphomas, resulting in a wide range of genetic alterations that have been reported across all types of lymphomas. As many of these changes are now incorporated into the World Health Organization’s defined criteria for the diagnostic evaluation of patients with lymphoid neoplasms, their accurate identification is crucial. Even if many alterations are not routinely evaluated in daily clinical practice, they may still have implications in risk stratification, treatment, prognosis or disease monitoring. Moreover, some alterations can be used for targeted treatment. The...
High throughput sequencing (HTS) is increasingly important in determining cancer diagnoses, with sub...
Non-Hodgkin lymphomas (NHL), the 6th most frequent cancer in western countries, represent a large gr...
Although survival rates for lymphoproliferative disorders are steadily increasing both in the US and...
Lymphomas encompass a diverse group of malignant lymphoid neoplasms. Over recent years much scienti...
With the introduction of large-scale molecular profiling methods and high-throughput sequencing tech...
For the past 20 years most malignant lymphomas have been classified as clinicopathological entities,...
Modern achievements in genomics and cancer biology have provided an unprecedented body of knowledge ...
In recent years, DNA-arrays, gene expression profiling and next-generation sequencing have elucidate...
For the past 20 years most malignant lymphomas have been classified as clinicopathological entities,...
Careful histopathologic examination remains the cornerstone in the diagnosis of the clinically and b...
Similar to the inherent clinical heterogeneity of most, if not all, lymphoma entities, the genetic l...
Lymphoma is a group of lymphoid neoplasms originating from B or T lymphocytes. Lymphoma is now the f...
We review the problem of lymphoma classification in the light of the Revised European-American Lymph...
Similar to the inherent clinical heterogeneity of most, if not all, lymphoma entities, the genetic l...
Recent years have brought an explosion of new diagnostic tools to the pathology of lymphomas, which ...
High throughput sequencing (HTS) is increasingly important in determining cancer diagnoses, with sub...
Non-Hodgkin lymphomas (NHL), the 6th most frequent cancer in western countries, represent a large gr...
Although survival rates for lymphoproliferative disorders are steadily increasing both in the US and...
Lymphomas encompass a diverse group of malignant lymphoid neoplasms. Over recent years much scienti...
With the introduction of large-scale molecular profiling methods and high-throughput sequencing tech...
For the past 20 years most malignant lymphomas have been classified as clinicopathological entities,...
Modern achievements in genomics and cancer biology have provided an unprecedented body of knowledge ...
In recent years, DNA-arrays, gene expression profiling and next-generation sequencing have elucidate...
For the past 20 years most malignant lymphomas have been classified as clinicopathological entities,...
Careful histopathologic examination remains the cornerstone in the diagnosis of the clinically and b...
Similar to the inherent clinical heterogeneity of most, if not all, lymphoma entities, the genetic l...
Lymphoma is a group of lymphoid neoplasms originating from B or T lymphocytes. Lymphoma is now the f...
We review the problem of lymphoma classification in the light of the Revised European-American Lymph...
Similar to the inherent clinical heterogeneity of most, if not all, lymphoma entities, the genetic l...
Recent years have brought an explosion of new diagnostic tools to the pathology of lymphomas, which ...
High throughput sequencing (HTS) is increasingly important in determining cancer diagnoses, with sub...
Non-Hodgkin lymphomas (NHL), the 6th most frequent cancer in western countries, represent a large gr...
Although survival rates for lymphoproliferative disorders are steadily increasing both in the US and...